Steps forward in gene therapy for hearing loss linked to rare disease
29 Aug 2023, 3 p.m.
An international team led by researchers at GOSH, UCL and the National Institute of Health and Care Research Great Ormond Street Hospital Biomedical Research Centre (NIHR GOSH BRC) have developed a gene therapy in mice that significantly reduces the hearing loss associated with Norrie disease.
Norrie disease is a rare but devastating genetic disorder that causes blindness and hearing loss, and it primarily affects boys. They are born blind and from about 12 years of age develop progressive hearing loss. This research is aimed at slowing or preventing the hearing loss and thus the dual sensory deprivation that severely restricts the lives of those with Norrie Disease.
Currently, the only possible treatment option is cochlear implants, which are only partly effective in Norrie Disease. This research in mice, published in EMBO, has shown how a gene therapy can be used to prevent the death of the vitally important hair cells in the cochlea – the snail shell-like part of the inner ear responsible for sensing sound - and stop the loss of hearing associated with Norrie Disease.
The team injected a gene therapy designed to restore the missing norrin protein. They showed that the abnormal blood vessels in the ears and eyes that develop in mice with Norrie disease are improved by the treatment. This could help prevent deafblindness as tests showed both better hearing and vision after the gene therapy treatment in mice.
Children with Norrie disease progressively lose their hearing because of a faulty gene called NDP, which is responsible for some of the structures in the inner ear.In our study we have shown that in mice with Norrie disease, we can correct this faulty gene by inserting billions of new ‘fixed’ copies into the bloodstream. This gene therapy appears to lead to better blood vessel structure in the inner ear and crucially we can see the sensory hairs are protected.
Being able to offer effective treatment could be life-changing for children who are seen at hospitals around the world, including at GOSH. Being blind can be challenging but treating or slowing the progression of hearing loss could mean the difference between independence as an adult, or not.
I hope that gene therapy for hearing loss caused by faulty genes will soon be available for patients. In this study we were able to reduce the progressive hearing loss in a Norrie disease model by gene therapy for the first time. The treatment in mice was successful not only for newborns but also when we treated at a stage comparable to children and young people. This is exciting progress as it lays the groundwork for future application in patients – this could be transformative for them and their families and carers.
We have previously shown that Norrie hearing loss coincides with loss of the sensory hair cells in the inner ear. While there may also be other factors involved, once lost, cochlear hair cells cannot regrow. This new work shows that NDP gene therapy can be very effective in preventing further damage to the hair cells and hearing in Norrie Disease in mice. Hearing is one of the most important senses. While sight loss is already established at birth for those with Norrie disease, this work shows how we might be able to help them keep their hearing – an incredibly important sense.
When this research was initially funded, patient advocacy group the Norrie Disease Foundation who provide vital support to families living with the condition, and part funded this research said: "Our hope is that this research will provide a treatment so our blind community don’t also become deaf. Currently, families are expected to deal and cope with the symptoms. Now there is a chance that one of the life-changing symptoms can be delayed or even stopped. There is potential for a brighter future for Norrie patients, and this gives a feeling of optimism. Whilst Norrie disease can’t currently be cured, it feels like we are one step closer to making the condition less devastating."
GOSH patient first in the UK to receive improved kidney transplant
Eight-year-old Aditi is the first child in the UK and on the NHS to be taken off immunosuppressants just one-month after kidney transplant at Great Ormond Street Hospital (GOSH).
A showcase of research
This summer saw the return of the NIHR GOSH BRC showcase.
Global genomic collaboration improves lives and treatment for children with epilepsy
An international research collaboration, including GOSH and our research partner UCL Institute of Child Health, has shown that a technique known as rapid genome sequencing can provide a diagnosis for 43 per cent of children with unexplained epilepsy.
Unlocking the mystery of long-lasting cancer treatment
Researchers from across GOSH, UCL GOS ICH and the Wellcome Sanger Institute have published new insights that explain why some children have a longer remission than others after having cutting-edge CAR T-cell therapy for leukaemia.